180 related articles for article (PubMed ID: 19356014)
41. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.
Huang L; Zhang T; Xie C; Liao X; Yu Q; Feng J; Ma H; Dai J; Li M; Chen J; Zang A; Wang Q; Ge S; Qin K; Cai J; Yuan X
PLoS One; 2013; 8(10):e77223. PubMed ID: 24143213
[TBL] [Abstract][Full Text] [Related]
42. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
[TBL] [Abstract][Full Text] [Related]
43. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
[TBL] [Abstract][Full Text] [Related]
44. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
45. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Ando Y; Fujita K; Sasaki Y; Hasegawa Y
Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
Ando M; Hasegawa Y; Ando Y
Invest New Drugs; 2005 Dec; 23(6):539-45. PubMed ID: 16267624
[TBL] [Abstract][Full Text] [Related]
47. UGT1A1 genotyping in patients undergoing treatment with irinotecan.
Innocenti F
Clin Adv Hematol Oncol; 2005 Nov; 3(11):843-4. PubMed ID: 16491625
[No Abstract] [Full Text] [Related]
48. Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients.
Hirasawa A; Zama T; Akahane T; Nomura H; Kataoka F; Saito K; Okubo K; Tominaga E; Makita K; Susumu N; Kosaki K; Tanigawara Y; Aoki D
J Hum Genet; 2013 Dec; 58(12):794-8. PubMed ID: 24088669
[TBL] [Abstract][Full Text] [Related]
49. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
Schulz C; Heinemann V; Schalhorn A; Moosmann N; Zwingers T; Boeck S; Giessen C; Stemmler HJ
World J Gastroenterol; 2009 Oct; 15(40):5058-66. PubMed ID: 19859999
[TBL] [Abstract][Full Text] [Related]
50. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
51. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
[TBL] [Abstract][Full Text] [Related]
52. Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine.
Paulík A; Nekvindová J; Filip S
Tumori; 2020 Apr; 106(2):87-94. PubMed ID: 30514181
[TBL] [Abstract][Full Text] [Related]
53. Irinotecan pharmacogenetics: influence of pharmacodynamic genes.
Hoskins JM; Marcuello E; Altes A; Marsh S; Maxwell T; Van Booven DJ; Paré L; Culverhouse R; McLeod HL; Baiget M
Clin Cancer Res; 2008 Mar; 14(6):1788-96. PubMed ID: 18347181
[TBL] [Abstract][Full Text] [Related]
54. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Mehra R; Murren J; Chung G; Smith B; Psyrri A
Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
[TBL] [Abstract][Full Text] [Related]
55. Pharmacogenetics of irinotecan metabolism and transport: an update.
Smith NF; Figg WD; Sparreboom A
Toxicol In Vitro; 2006 Mar; 20(2):163-75. PubMed ID: 16271446
[TBL] [Abstract][Full Text] [Related]
56. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
Fukuda M; Shimada M; Kitazaki T; Nagashima S; Hashiguchi K; Ebi N; Takayama K; Nakanishi Y; Semba H; Harada T; Seto T; Okamoto I; Ichinose Y; Sugio K
Thorac Cancer; 2017 Jan; 8(1):40-45. PubMed ID: 27883280
[TBL] [Abstract][Full Text] [Related]
57. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.
Fujita K; Kubota Y; Ishida H; Sasaki Y
World J Gastroenterol; 2015 Nov; 21(43):12234-48. PubMed ID: 26604633
[TBL] [Abstract][Full Text] [Related]
58. UGT1A and irinotecan toxicity: keeping it in the family.
Hoskins JM; McLeod HL
J Clin Oncol; 2009 May; 27(15):2419-21. PubMed ID: 19364959
[No Abstract] [Full Text] [Related]
59. Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects.
Toshimoto K; Tomaru A; Hosokawa M; Sugiyama Y
Pharm Res; 2017 Aug; 34(8):1584-1600. PubMed ID: 28397089
[TBL] [Abstract][Full Text] [Related]
60. Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
Johnson FM; Glisson BS
Nat Rev Clin Oncol; 2009 Oct; 6(10):562-3. PubMed ID: 19786998
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]